Tafasitamab
DrugTreatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
NCT Number: NCT06465433
This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Interested in participating?
Request Info18 year–99 year
All sexes
Interventional
Phase 2
Petz Aladar County Teaching Hospital, Győr, Hungary
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Time frame: up to approximately 2 years
Defined as any Adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after the last dose of study drug.
Contact information is provided by the study sponsor or research team.
Incyte Corporation Call Center (US)
CONTACT
Incyte Corporation Call Center (ex-US)
CONTACT
Incyte Corporation
Industry
An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05724121
Arrhythmias, Cardiac, Atrial Fibrillation
Bethesda, Maryland, United States
View Trial DetailsNCT03486873
Hematologic Diseases, Hematologic Malignancies
Tucson, Arizona, United States
View Trial DetailsNCT07285668
Hematologic Diseases, Hematologic Malignancies
Madison, Wisconsin, United States
View Trial DetailsNCT04728893
Blood Protein Disorders, Cardiovascular Diseases
Springdale, Arkansas, United States
View Trial Details